PT-141 10mg

Research

Scientific Research on the PT-141 Peptide

PT-141 (Bremelanotide) is a synthetic peptide derived from melanocortin, widely investigated in scientific research due to its effects on the central nervous system, especially related to sexual arousal and desire. Its primary action occurs through the activation of melanocortin receptors MC3R and MC4R, which play a central role in modulating sexual behavior.

PT-141 and Male Sexual Dysfunction

Clinical studies have demonstrated that PT-141 is capable of inducing significant erectile responses in both healthy men and individuals with mild to moderate erectile dysfunction. These effects are dose-dependent and present a relatively rapid onset, with responses observed approximately 30 minutes after administration.¹

Additional research indicates that PT-141 may be effective in individuals who do not respond adequately to phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil. This profile suggests its potential as an alternative or experimental complement in studies on refractory erectile dysfunction.²

PT-141 and Female Sexual Dysfunction

Female sexual dysfunction (FSD) is a multifactorial condition, with an estimated prevalence of approximately 30% of women in North America and Europe, involving physiological, psychological, and interpersonal components.

Experimental models have demonstrated that PT-141 selectively stimulates behaviors related to sexual motivation in females, considered analogous to sexual arousal in humans, without interfering with other behavioral patterns. These findings suggest a specific effect on appetitive sexual behavior, supporting its potential in research aimed at hypoactive sexual desire disorder (HSDD).³

Preliminary clinical data also indicate that PT-141 may promote increased sexual desire and libido in women, further reinforcing its scientific interest in this field.⁴

Mechanism of Action and Neurogenic Effects

Unlike PDE5 inhibitors, which act predominantly by increasing genital blood flow through nitric oxide signaling, the effects of PT-141 are essentially neurogenic.

The peptide acts by modulating central neural circuits, increasing dopaminergic tone in limbic areas associated with sexual desire and reducing inhibitory signals mediated by serotonergic pathways. This mechanism highlights PT-141 as a relevant tool for neuroendocrine and behavioral studies related to sexuality.⁵

Final Considerations

Scientific research on PT-141 has expanded the understanding of the central mechanisms involved in sexual arousal and desire. Its use remains restricted to experimental and research contexts, and adherence to appropriate scientific, regulatory, and ethical protocols is essential.

References

1. Diamond, L., Earle, D., Rosen, R., Willett, M., & Molinoff, P. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16, 51–59. https://doi.org/10.1038/sj.ijir.3901139
2. Rosen, R., Diamond, L., Earle, D., Shadiack, A., & Molinoff, P. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®. International Journal of Impotence Research, 16, 135–142. https://doi.org/10.1038/sj.ijir.3901200
3. Pfaus, J., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 101(27), 10201–10204. https://doi.org/10.1073/PNAS.0400491101
4. Shadiack, A., Sharma, S., Earle, D., Spana, C., & Hallam, T. (2007). Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry, 7(11), 1137–1144. https://doi.org/10.2174/156802607780906681
5. Pfaus, J. G., Sadiq, A., Spana, C., & Clayton, A. H. (2022). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums, 27(3), 281–289. https://doi.org/10.1017/S109285292100002X

Scientific Reviewer

The content was reviewed by Ky H. Le, MD. Dr. Ky H. Le is a family medicine physician in Aiea, Hawaii. He received his medical degree from St. George's University School of Medicine and has been practicing for more than 20 years. He has expertise in treating obesity, diabetes, hypertension, and high blood pressure, among other conditions – see all areas of expertise. Dr. Ky H. Le accepts Medicare, Aetna, Humana, Blue Cross, United Healthcare.

Ref.: https://health.usnews.com/doctors/ky-le-371599#expertise